New combo aims to boost cancer-killing radiation in hard-to-treat tumors

NCT ID NCT05178693

Recruiting now Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Nov 25, 2025 · Last updated Jun 16, 2026 · Updated 29 times

Summary

This early-stage study tests whether taking a 5-day course of the drug ASTX727 before standard Lutathera radiation therapy can help the radiation target cancer cells more effectively. About 27 adults with metastatic neuroendocrine tumors will receive the combination. The goal is to see if the priming drug can turn on a receptor that makes cancer cells more visible to the radiation, potentially improving treatment response while monitoring side effects and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hammersmith Hospital
RECRUITING

London, London, City of, W12 0HS, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS